JW Therapeutics Revenue and Competitors

上海,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • JW Therapeutics's estimated annual revenue is currently $20.3M per year.(i)
  • JW Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • JW Therapeutics has 131 Employees.(i)
  • JW Therapeutics grew their employee count by -5% last year.

JW Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is JW Therapeutics?

JW Therapeutics is an innovative biotech company focusing on the latest clinical cell therapy technology. It is commited to the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring new hope. JW Therapeutics was co-founded by WuXi AppTec, Juno Therapeutics in February 2016.

keywords:N/A

N/A

Total Funding

131

Number of Employees

$20.3M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

JW Therapeutics News

2022-04-17 - Chinese Regulators Clear JW Therapeutics' Carteyva IND for ...

NEW YORK – JW Therapeutics said on Wednesday that China's National Medical Products Administration (NMPA) has cleared an investigational new...

2022-03-30 - JW Therapeutics Announces Receipt of Breakthrough ...

JW Therapeutics (HKEx: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...

2022-03-30 - JW Therapeutics Announces IND Approval for the Pivotal ...

SHANGHAI, March 31, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.8M134-15%N/A
#2
$49.5M150-6%N/A
#3
$33.8M152-3%N/A
#4
$61.7M170-1%N/A
#5
$43.2M2150%N/A